{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:11:41Z","timestamp":1784153501562,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T00:00:00Z","timestamp":1306195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T00:00:00Z","timestamp":1306195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/leu.2011.109","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T10:47:43Z","timestamp":1306234063000},"page":"1444-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol"],"prefix":"10.1038","volume":"25","author":[{"given":"K A","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,24]]},"reference":[{"key":"BFleu2011109_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","volume":"96","author":"S Kitada","year":"2000","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393\u2013397.","journal-title":"Blood"},{"key":"BFleu2011109_CR2","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804.422k36_3804_3816","volume":"92","author":"JC Byrd","year":"1998","unstructured":"Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804\u20133816.","journal-title":"Blood"},{"key":"BFleu2011109_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","volume":"29","author":"IW Flinn","year":"2005","unstructured":"Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29: 1253\u20131257.","journal-title":"Leuk Res"},{"key":"BFleu2011109_CR4","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","volume":"11","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11: 4176\u20134181.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011109_CR5","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","volume":"27","author":"TS Lin","year":"2009","unstructured":"Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012\u20136018.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399\u2013404.","journal-title":"Blood"},{"key":"BFleu2011109_CR7","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","volume":"113","author":"MA Phelps","year":"2009","unstructured":"Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637\u20132645.","journal-title":"Blood"},{"key":"BFleu2011109_CR8","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O\u2019Brien S et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BFleu2011109_CR9","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910\u20131916.","journal-title":"N Engl J Med"},{"key":"BFleu2011109_CR10","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3324\/haematol.13290","volume":"93","author":"P Tosi","year":"2008","unstructured":"Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008; 93: 1877\u20131885.","journal-title":"Haematologica"},{"key":"BFleu2011109_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A . Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149: 578\u2013586.","journal-title":"Br J Haematol"},{"key":"BFleu2011109_CR12","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS . Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767\u20132778.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR14","doi-asserted-by":"crossref","unstructured":"Dann EJ, Gillis S, Polliack A, Okon E, Rund D, Rachmilewitz EA . Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. 1993; 329: 1547\u20131548.","DOI":"10.1056\/NEJM199311183292106"},{"key":"BFleu2011109_CR15","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1200\/JCO.1998.16.7.2313","volume":"16","author":"BD Cheson","year":"1998","unstructured":"Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM . Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 2313\u20132320.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR16","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","volume":"25","author":"S O\u2019Brien","year":"2007","unstructured":"O\u2019Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114\u20131120.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR17","first-page":"1268","volume":"85","author":"G Marotta","year":"2000","unstructured":"Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F . Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268\u20131270.","journal-title":"Haematologica"},{"key":"BFleu2011109_CR18","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","volume":"28","author":"W-G Tong","year":"2010","unstructured":"Tong W-G, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD et al. Phase I and pharmacologic study of SNS-032, a potentand selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010; 28: 3015\u20133022: JCO.2009.2026.1347.","journal-title":"J Clin Oncol"},{"key":"BFleu2011109_CR19","first-page":"886","volume":"114","author":"JM Flynn","year":"2009","unstructured":"Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA et al. The cyclin dependent kinase inhibitor SCH 727965 demonstrates promising pre-clinical and early clinical activity in chronic lymphocytic leukemia. ASH Annu Meet Abstr 2009; 114: 886 (abstract).","journal-title":"ASH Annu Meet Abstr"},{"key":"BFleu2011109_CR20","first-page":"3161","volume":"112","author":"V Lock","year":"2008","unstructured":"Lock V, Cooke L, Yule M, Thompson NT, Croce KD, Lyons JF et al. AT7519, a potent multi-targeted CDK inhibitor, is active in CLL patient samples independent of stage. ASH Annu Meet Abstr 2008; 112: 3161 (abstract).","journal-title":"ASH Annu Meet Abstr"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:00:40Z","timestamp":1648735240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,24]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["BFleu2011109"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.109","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,24]]},"assertion":[{"value":"1 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JCB and MRG are both inventors on a use patent related to the administration of flavopiridol. This patent has not been issued and currently has no monetary value.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}